4月29日 - ** 制药商BridgeBio Pharma BBIO.O盘后股价上涨7.08%至39美元
* (link) * 根据LSEG汇编的数据，该公司第一季度Attruby销售额为3670万美元，超过预期的1310万美元。
** Attruby用于治疗 (link) 成人转甲状腺素淀粉样心肌病(ATTR-CM)，这种病的转甲状腺素蛋白在心脏中积聚，可导致器官衰竭
** 自2024年11月获得FDA批准以来，截至4月25日，已有756家医疗机构为2072名患者开具了Attruby处方。
** 迄今为止，Attruby 的上市继续保持强劲势头，并提高了市场预期--BMO Capital Markets
** 股价在过去一年中上涨了约 32
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.